Bijlage 1 — Prevalentie-ontwikkeling 2010–2011 per morbiditeitsrisicoklasse per fkg 2011 Beleidsregels vereveningsbijdrage zorgverzekering 2011
Prevalentie-ontwikkeling 2010–2011 per morbiditeitsrisicoklasse per fkg 2011
FKG somatisch model
Mannen | 0 | 1 | 2 | 3 | 4 | 5
Leeftijd | | Glaucoom | Schildklieraandoeningen | Antipsychotica | Antidepressiva | Hoog cholesterol
0 t/m 17 | 0,999988 | 1,153509 | 1,050184 | 1,086949 | 1,087611 | 1,253814
18 t/m 29 | 0,999436 | 1,027562 | 1,028333 | 0,986864 | 0,986745 | 1,037685
30 t/m 44 | 0,998512 | 1,035136 | 1,029566 | 1,032488 | 0,99281 | 1,033492
45 t/m 59 | 0,994089 | 0,986797 | 1,037156 | 1,056312 | 0,996855 | 1,046631
60 t/m 74 | 0,980084 | 1,007702 | 1,02656 | 1,083214 | 1,007215 | 1,076217
75 e.o. | 0,962878 | 1,009005 | 1,03962 | 1,157967 | 0,98331 | 1,131441
Vrouwen | 0 | 1 | 2 | 3 | 4 | 5
Leeftijd | | Glaucoom | Schildklieraandoeningen | Antipsychotica | Antidepressiva | Hoog cholesterol
0 t/m 17 | 0,999989 | 1,038114 | 1,023738 | 1,153602 | 0,950449 | 1,275496
18 t/m 29 | 0,999723 | 1,122349 | 1,031324 | 0,988669 | 0,960717 | 1,019108
30 t/m 44 | 0,998722 | 1,028645 | 1,04361 | 1,013352 | 0,977981 | 1,051626
45 t/m 59 | 0,993506 | 0,960788 | 1,038453 | 1,044875 | 0,997902 | 1,077686
60 t/m 74 | 0,983422 | 1,004917 | 1,033149 | 1,049194 | 0,99533 | 1,093041
75 e.o. | 0,975557 | 0,997794 | 1,03099 | 1,185787 | 0,983926 | 1,153598
Mannen | 6 | 7 | 8 | 9 | 10 | 11
Leeftijd | Diabetes type IIb | COPD/zware astma | Astma | Diabetes type IIa | Epilepsie | Ziekte van Crohn
0 t/m 17 | 1,240091 | 0,86477 | 0,984057 | 1,014778 | 1,018172 | 1,046245
18 t/m 29 | 1,240091 | 0,990192 | 1,023472 | 1,014778 | 1,025115 | 0,999847
30 t/m 44 | 1,028848 | 1,008619 | 1,016719 | 1,014778 | 0,999848 | 1,049296
45 t/m 59 | 1,021583 | 1,037964 | 1,022274 | 1,026526 | 1,011285 | 1,020003
60 t/m 74 | 0,976249 | 1,014464 | 0,998851 | 1,035197 | 1,006136 | 1,050207
75 e.o. | 0,967546 | 1,003493 | 0,992455 | 1,039099 | 1,007737 | 1,040791
Vrouwen | 6 | 7 | 8 | 9 | 10 | 11
Leeftijd | Diabetes type IIb | COPD/zware astma | Astma | Diabetes type IIa | Epilepsie | Ziekte van Crohn
0 t/m 17 | 1,048143 | 0,964369 | 0,984821 | 1,040879 | 1,028778 | 0,953647
18 t/m 29 | 1,048143 | 0,954478 | 1,033318 | 1,040879 | 1,01324 | 0,987154
30 t/m 44 | 1,033323 | 0,978739 | 1,035264 | 1,040879 | 0,992799 | 1,010962
45 t/m 59 | 1,023801 | 1,069696 | 1,0379 | 1,0121 | 0,998449 | 1,009953
60 t/m 74 | 0,963835 | 1,042719 | 1,027604 | 1,00918 | 1,020757 | 1,056433
75 e.o. | 0,936615 | 1,023603 | 1,02489 | 1,015317 | 0,993306 | 1,017788
Mannen | 12 | 13 | 14 | 15 | 16 | 17
Leeftijd | Hartaandoening | Reuma: TNF a blokkers | Overige reuma middelen | Parkinson | Diabetes type I | Transplantaties
0 t/m 17 | 0,800307 | 1,388229 | 1,092211 | 1,08037 | 1,00861 | 0,982339
18 t/m 29 | 0,96201 | 1,388229 | 0,994685 | 1,08037 | 1,023271 | 1,093333
30 t/m 44 | 0,978488 | 1,279156 | 1,015529 | 1,08037 | 1,025083 | 1,045369
45 t/m 59 | 0,968564 | 1,244567 | 1,009995 | 1,042034 | 1,027631 | 1,039741
60 t/m 74 | 0,973212 | 1,24035 | 1,030978 | 1,029179 | 1,032583 | 1,057036
75 e.o. | 0,983421 | 1,324874 | 1,025357 | 1,04114 | 1,051252 | 1,057498
Vrouwen | 12 | 13 | 14 | 15 | 16 | 17
Leeftijd | Hartaandoening | Reuma: TNF a blokkers | Overige reuma middelen | Parkinson | Diabetes type I | Transplantaties
0 t/m 17 | 0,841433 | 1,106186 | 1,065943 | 0,910856 | 1,012018 | 0,998626
18 t/m 29 | 0,983035 | 1,391008 | 1,048136 | 0,910856 | 1,018713 | 1,08416
30 t/m 44 | 1,0296 | 1,305533 | 1,028635 | 0,910856 | 1,020195 | 1,056104
45 t/m 59 | 0,984681 | 1,200878 | 1,035661 | 1,039078 | 1,01853 | 1,040792
60 t/m 74 | 0,975911 | 1,146075 | 1,048307 | 1,02006 | 1,006854 | 1,061283
75 e.o. | 0,986095 | 1,183035 | 1,066105 | 1,019039 | 1,019355 | 1,0963
Mannen | 18 | 19 | 20 | 21 | 22 | 23
Leeftijd | Cystic fibrosis/pancreas | Aand. van hersenen/ruggemerg | Kanker | HIV/Aids | Nieraandoeningen | Groeihormonen
0 t/m 17 | 1,003051 | 1,10091 | 1,059144 | 1,087816 | 0,951947 | 1,11296
18 t/m 29 | 1,015688 | 1,116876 | 1,059144 | 1,218175 | 0,951947 | 0,874078
30 t/m 44 | 0,919975 | 1,00881 | 1,148315 | 1,10772 | 1,052378 | 1,090919
45 t/m 59 | 1,049724 | 1,046512 | 1,026602 | 1,138958 | 0,890545 | 1,215473
60 t/m 74 | 1,071085 | 0,994479 | 1,050193 | 1,161548 | 0,931651 | 1,127033
75 e.o. | 1,108452 | 1,052993 | 1,174186 | 1,161548 | 1,057905 | 1,127033
Vrouwen | 18 | 19 | 20 | 21 | 22 | 23
Leeftijd | Cystic fibrosis/pancreas | Aand. van hersenen/ruggemerg | Kanker | HIV/Aids | Nieraandoeningen | Groeihormonen
0 t/m 17 | 0,992842 | 0,925665 | 0,878249 | 1,148372 | 0,977944 | 1,07807
18 t/m 29 | 0,969514 | 1,002999 | 0,878249 | 1,046419 | 0,977944 | 0,977892
30 t/m 44 | 1,00387 | 1,014593 | 1,215492 | 1,061073 | 0,877689 | 1,127152
45 t/m 59 | 1,040322 | 1,033666 | 1,097527 | 1,18985 | 0,80588 | 1,050593
60 t/m 74 | 1,0819 | 1,067895 | 1,003604 | 1,169688 | 0,93504 | 1,131759
75 e.o. | 1,041092 | 1,043934 | 1,10616 | 1,169688 | 1,076612 | 1,131759
FKG GGZ model
Mannen | 0 | 1
Leeftijd | | Psych. aand.
0 t/m 17 | 0,997684 | 1,135244
18 t/m 29 | 0,999295 | 1,043923
30 t/m 44 | 0,999415 | 1,017779
45 t/m 59 | 0,999388 | 1,013628
60 t/m 74 | 0,99935 | 1,018727
75 e.o. | 0,999056 | 1,021842
Vrouwen | 0 | 1
Leeftijd | | Psych. aand.
0 t/m 17 | 0,999282 | 1,177205
18 t/m 29 | 1,000224 | 0,99003
30 t/m 44 | 1,000633 | 0,988094
45 t/m 59 | 0,999706 | 1,00388
60 t/m 74 | 0,999936 | 1,000973
75 e.o. | 0,999438 | 1,007468
Bron: College voor zorgverzekeringen
- Regeling
- Beleidsregels vereveningsbijdrage zorgverzekering 2011
- Soort
- ZBO-regeling
- Geldend vanaf
- 03-10-2012
- BWB-id
- BWBR0029624
- Versie
- 2012-10-03_0